Melatonin in rheumatoid arthritis

Survey the effect of melatonin supplementation on clinical symptoms and sleep quality in patients with rheumatoid arthritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191231045964N1

Enrollment

Registered

2020-08-15

Start date

2020-05-04

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis. Rheumatoid arthritis with rheumatoid factor

Interventions

Intervention 1: Intervention group: One 3 mg melatonin capsule, daily, for 2 months. Intervention 2: Control group: One 3 mg placebo capsule, daily, for 2 months.

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: They are eighteen to fifty years old Patients are selected from both sexes Patients with rheumatoid arthritis Patients' body mass index is between 18/5_30

Exclusion criteria

Exclusion criteria: People taking antidepressants and sedatives People who use alcohol and cigarettes Taking antioxidant supplements within 3 months prior People taking anticoagulants Pregnant and lactating women Any disease except rheumatoid arthritis

Design outcomes

Primary

Measure	Time frame
Sleep quality. Timepoint: Before and after the intervention. Method of measurement: Questionnaire.;Intensity of pain. Timepoint: Before and after the intervention. Method of measurement: VAS Questionnaire.;Illness severity. Timepoint: Before and after the intervention. Method of measurement: DAS-28 Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTayebeh Palimi

Ahvaz University of Medical Sciences

palimitayebeh@gmail.com+98 61 3373 8383

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026